BPA #36E79727A0002

Blanket Purchase Agreement for Pharmaceutical Products with Travere Therapeutics

This award represents a blanket purchase agreement (BPA), a streamlined indefinite-delivery vehicle designed to procure pharmaceuticals efficiently. The recipient, Travere Therapeutics, Inc., is a pharmaceutical company specializing in treatments for rare and serious conditions, reflecting its expertise aligned with the contract's scope. The contract facilitates a substantial procurement of pharmaceutical products, supporting ongoing government health initiatives by ensuring a stable supply of essential medicines. The BPA covers a one-year performance period, commencing in the fall of 2026, providing flexibility for multiple orders over this timeframe. This contract builds upon a prior Federal Supply Schedule (FSS) agreement under Schedule 65 I B, which established foundational access to Travere’s drug portfolio under a non-competitive, pre-negotiated vehicle to expedite acquisition. The current BPA leverages this arrangement, enhancing procurement efficiency for the agency’s pharmaceutical needs without the need for separate competitive solicitations. No subcontractors are listed, and the streamlined nature of the BPA and FSS vehicles underscores the government's intent to maintain reliable access to necessary medical products while supporting public health goals.

Description

BPA FOR FILSPARI

View original record